Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion
Not Applicable
Completed
- Conditions
- HypertensionHypercholesterolemia
- Interventions
- Drug: Placebo
- Registration Number
- NCT01126684
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Brief Summary
To evaluate the possible effects of atorvastatin on ambulatory blood pressure, urinary albumin excretion, insulin resistance and arterial stiffness in hypertensive patients, beyond those on lipid profile. Glycemic parameters, "novel" cardiovascular risk factors and safety parameters will be also evaluated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- LDL-C>130 or >160 mg/dL (depending on the total risk according to the most recent recommendations25).
- no previous hypolipidemic medication
- ability to provide Informed Consent.
Exclusion Criteria
- pregnancy or lactation
- myocardial infarction or unstable angina within the past 6 months
- heart failure NYHA class III-IV
- renal disease (SCr>3 mg/dL or proteinuria>3g/d)
- liver disease
- history of malignancy
- history of drug or alcohol abuse
- treatment with corticosteroids
- any other condition with poor prognosis
- inability to provide Informed Consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Atorvastatin Atorvastatin -
- Primary Outcome Measures
Name Time Method Ambulatory blood pressure Six months
- Secondary Outcome Measures
Name Time Method Urinary Albumin Excretion Six months Insulin Sensitivity Six months Arterial Stiffness Six months Urinary levels of nephrin Six months Urinary levels of podocalyxin Six months Urinary levels of Endothelin-1 Six months Urinary levels of Asymmetric Dimethylarginine Six months Urinary levels of indices of oxidative stress Six months
Trial Locations
- Locations (1)
AHEPA University Hospital of Thessaloniki
🇬🇷Thessaloniki, Greece